… that the effect of SHP2 inhibition in KRAS-mutant cancers could be recapitulated with RTK
inhibitors. We first evaluated the efficacy of an RTK inhibitor cocktail, targeting ERBBs, FGFRs, …

… were associated with genomic aberrations that were associated with the RAS/RTK pathway
79 . … Selective inhibitors targeting specific KRAS mutations are urgently needed to effectively …

… MEK inhibition, using an SHP2 inhibitor (SHP099) that blocks RAS activation mediated
by multiple RTKs. We find that RTK-driven feedback activation widely exists in KRAS-mutant …

… upstream signaling with RTK inhibitors that increase the activity of KRAS G12C … RTK
signaling to KRAS. Accordingly, SHP2 inhibitors are active in cancers driven by KRAS mutations …

… effect of RTK inhibition may be … inhibition could be effective in patients with KRAS mutant
lung tumors [[114]]. Interestingly, CDK4/6 inhibitors also synergized with KRAS G12C inhibitors …

… lung cancer, EMT has been shown to play a defining role in the feedback reactivation of
RTK signaling following MEK inhibition. In epithelial-like cells, this feedback was mediated by …

… survival in KRAS mutant cancer cells, (… inhibitor of proximal RTK signaling may be a common
therapeutic strategy to enhance RTK inhibitor efficacy and treat cancers dependent on RTK …

… KRAS mutations impart insensitivity to inhibitors of upstream … mutations within KRAS and
associated RTK and MAPK signaling molecules, acquired resistance to KRAS G12C inhibitors …

… Research on direct inhibition of KRAS mutations date back to the discovery of RAS-… Unlike
NSCLC cell lines, the KRAS (G12C) CRC models have a high basal level of RTK activation …

… for inhibiting KRAS signaling and blocking KRAS functions, in … nanoparticles together with
the RTK inhibitor erlotinib. This … thus a mechanistic understanding of KRAS mutations and their …